Home Cart Sign in  
Chemical Structure| 870964-67-3 Chemical Structure| 870964-67-3

Structure of Evocalcet
CAS No.: 870964-67-3

Chemical Structure| 870964-67-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Evocalcet is an orally active calcium-sensing receptor (CaSR) agonist that effectively inhibits the secretion of parathyroid hormone (PTH). It is suitable for research and treatment of hyperparathyroidism.

Synonyms: KHK7580; MT-4580

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Evocalcet

CAS No. :870964-67-3
Formula : C24H26N2O2
M.W : 374.48
SMILES Code : O=C(O)CC1=CC=C(N2C[C@@H](N[C@@H](C3=C4C=CC=CC4=CC=C3)C)CC2)C=C1
Synonyms :
KHK7580; MT-4580
MDL No. :MFCD30533424

Safety of Evocalcet

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Evocalcet

GPCR

Isoform Comparison

Biological Activity

Description
Evocalcet (KHK7580) functions as an orally administered agonist for the calcium-sensing receptor (CaSR), effectively suppressing the secretion of parathyroid hormone (PTH) from parathyroid gland cells. This characteristic makes Evocalcet a valuable agent for hyperparathyroidism research[1].[2].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03280264 Parathyroid Carcinoma|Primary ... More >>Hyperparathyroidism Less << PHASE3 COMPLETED 2019-04-09 Osaka City University Hospital... More >>, ōsaka, Japan Less <<
NCT02143271 Secondary Hyperparathyroidism PHASE1 COMPLETED 2025-12-14 Kyowa Hakko Kirin, Tokyo, Japa... More >>n Less <<
NCT02549417 Secondary Hyperparathyroidism PHASE3 COMPLETED 2016-12-22 For additional information reg... More >>arding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan Less <<
NCT01935856 Hyperparathyroidism PHASE1|PHASE2 COMPLETED 2025-03-14 For additional information reg... More >>arding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan Less <<
NCT02549404 Secondary Hyperparathyroidism PHASE3 COMPLETED 2016-12-28 For additional information reg... More >>arding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.67mL

0.53mL

0.27mL

13.35mL

2.67mL

1.34mL

26.70mL

5.34mL

2.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories